FDA Grants Fast Track Designation to SBT101, the First Investigational AAV-Based Gene Therapy for…
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, announced that the U.S. Food…
Read More...
Read More...
